Appropriate use of immune checkpoint inhibitors and immunotherapy differs in adults with unresectable, metastatic cutaneous ...
Expanded Access and Right To Try Requests: The Community Oncologist's Experience We hypothesized that because of availability of ICIs, systemic therapy use in the last 30 days of life (DOL) would have ...
Phase I and Pharmacokinetic Study of the Ribonucleotide Reductase Inhibitor, 3-Aminopyridine-2-Carboxaldehyde Thiosemicarbazone, Administered by 96-Hour Intravenous Continuous Infusion Virus-directed ...
Breaking News: Trump administration impacts continue to roil the life sciences sector Home » Autologous B-cell therapy WFX-001 corrects systemic α-GAL enzyme deficiency in vivo ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results